Physician profile
Raj Jeevan
NPI 1851349682
$4,801.06
in general payments reported to CMS, 2019-2025
34 companies · $1,127 in 2025
The $1,127 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $394 · 2021: $473 · 2022: $532 · 2023: $440 · 2024: $1,176 · 2025: $1,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,654 · Education: $89.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,654.11 |
| Education | $89.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $672.50 | 2019-2025 | Veltassa, Korsuva |
| Novartis Pharmaceuticals Corporation | $508.35 | 2019-2025 | |
| Amgen INC. | $390.14 | 2019-2025 | Krystexxa, Tavneos, Repatha |
| Novo Nordisk INC | $317.94 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Mallinckrodt Hospital Products INC. | $297.33 | 2020-2025 | Acthar, Terlivaz |
| Fresenius USA Marketing, INC. | $243.33 | 2019-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $234.07 | 2020-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $205.40 | 2023-2025 | |
| Opko Pharmaceuticals, LLC | $190.81 | 2019-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $178.40 | 2021-2025 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.76 | 2023-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $158.28 | 2022 | |
| Sumitomo Pharma America, INC. | $149.58 | 2023-2025 | Gemtesa |
| Aurinia Pharma U.S., INC. | $126.65 | 2021-2025 | Lupkynis |
| Travere Therapeutics, INC. | $87.30 | 2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $86.22 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $79.07 | 2024-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $71.65 | 2022-2024 | Benlysta, Jesduvroq |
| Mallinckrodt Enterprises LLC | $63.78 | 2019 | |
| Urovant Sciences INC | $63.12 | 2022 | |
| Akebia Therapeutics INC | $60.42 | 2019 | |
| Lundbeck LLC | $59.13 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $58.38 | 2023-2025 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $46.70 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $46.10 | 2019 | |
| Horizon Therapeutics Plc | $44.36 | 2019-2023 | Krystexxa |
| Astellas Pharma US INC | $42.96 | 2019-2020 | |
| Baxter Healthcare | $30.60 | 2023 | Renal - Extraneal Solution |
| Takeda Pharmaceuticals U.S.A., INC. | $24.46 | 2022 | |
| Shield Therapeutics INC | $22.28 | 2024 | |
| Arbor Pharmaceuticals, INC. | $17.77 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $17.65 | 2023 | |
| Shire North American Group INC | $14.95 | 2019 | |
| Daiichi Sankyo INC. | $13.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raj Jeevan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.